Edition:
United States

People: Galapagos NV (GLPG.AS)

GLPG.AS on Amsterdam Stock Exchange

152.75EUR
17 Jul 2019
Change (% chg)

-- (--)
Prev Close
€152.75
Open
--
Day's High
--
Day's Low
--
Volume
--
Avg. Vol
438,881
52-wk High
€155.50
52-wk Low
€74.48

Wigerinck, Piet 

Dr. Piet Wigerinck, Ph.D. has served as Member of the Executive Committee, Chief Scientific Officer of Galapagos NV since April 18, 2012. He was Senior Vice President - Development from April 1, 2008. Dr. Wigerinck joined the Company in April 2008 from Tibotec (a subsidiary of Johnson & Johnson) where he was Vice President of Drug Discovery, Early Development and CM&C, and Member of the Management Board. He started his professional career as medicinal chemist at Janssen Research Foundation in 1992. He then joined Tibotec in 1998, where, under his leadership, TMC114 (PrezistaTM) and TMC435 (Olysio) were selected and moved forward into clinical trials. He brings over 15 years of research and development experience from both big pharmaceuticals and biotech to Galapagos. Dr. Wigerinck holds a Doctorate in Philosophy from the Catholic University of Louvain and is inventor on more than 25 patent applications.

Basic Compensation

Total Annual Compensation, --
Restricted Stock Awards, --
Long-Term Incentive Plans, --
All Other, --
Fiscal Year Total, --

Options Compensation

  Quantity Market Value
Exercisable -- --
Unexercisable -- --
Exercised -- --